다중암 조기 진단(MCED) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Multi Cancer Early Detection Market size is expected to reach USD 8.79 Billion in 2034 from USD 2.49 Billion (2025) growing at a CAGR of 15.07% during 2026-2034.

The global multi cancer early detection market is experiencing strong growth as healthcare systems focus on identifying cancer at its earliest stages. Multi cancer early detection tests are designed to detect signals from multiple types of cancer using a single screening test. These technologies often rely on advanced genomic and biomarker analysis to identify cancer-related changes in blood samples. Early detection significantly improves treatment outcomes and survival rates for cancer patients.

Advancements in molecular diagnostics and next-generation sequencing technologies are driving innovation in this market. Researchers and biotechnology companies are developing highly sensitive tests capable of detecting small traces of cancer-related genetic material in the bloodstream. Healthcare providers are increasingly adopting early detection screening programs to improve population health and reduce the burden of late-stage cancer treatments.

In the future, the market is expected to grow as precision medicine and personalized healthcare continue to advance. Large-scale clinical studies and regulatory approvals will help expand the availability of multi cancer screening tests. As awareness about preventive healthcare increases, multi cancer early detection technologies are likely to become an important part of routine medical screening programs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Gene Panel, LDT, & Others
• Liquid Biopsy

By End-use

• Hospitals
• Diagnostic Laboratories
• Other End-users

COMPANIES PROFILED

• AnPac BioMedical Science Co Ltd, Burning Rock Biotech Limited, EarlyDiagnostics, Elypta AB, Exact Sciences Corporation, Freenome Holdings Inc, Genecast Biotechnology Co Ltd, Guangzhou AnchorDx Medical Co Ltd, Guardant Health Inc, Illumina Inc GRAIL Inc, Micronoma Inc, Oncocyte Corporation, Roche Holding AG Foundation Medicine Inc, SeekIn Inc, Singlera Genomics Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MULTI CANCER EARLY DETECTION MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Gene Panel, LDT, & Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MULTI CANCER EARLY DETECTION MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other End-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MULTI CANCER EARLY DETECTION MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MULTI CANCER EARLY DETECTION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AnPac Bio-Medical Science Co. Ltd
  • 8.2.2 Burning Rock Biotech Limited
  • 8.2.3 EarlyDiagnostics
  • 8.2.4 Elypta AB
  • 8.2.5 Exact Sciences Corporation
  • 8.2.6 Freenome Holdings Inc
  • 8.2.7 Genecast Biotechnology Co. Ltd
  • 8.2.8 Guangzhou AnchorDx Medical Co. Ltd
  • 8.2.9 Guardant Health Inc
  • 8.2.10 Illumina Inc. (GRAIL Inc.)
  • 8.2.11 Micronoma Inc
  • 8.2.12 Oncocyte Corporation
  • 8.2.13 Roche Holding AG (Foundation Medicine Inc.)
  • 8.2.14 SeekIn Inc
  • 8.2.15 Singlera Genomics Inc